Tango Therapeutics (TNGX) EBITDA (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly EBITDA of -$48.8 million for Q1 2026, down 14.67% year-over-year from -$57.2 million in Q1 2025, and down 16.49% quarter-over-quarter from -$41.9 million in Q4 2025.
Tango Therapeutics (TNGX) EBITDA (2020 - 2026) Analysis & Trends
Tango Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$48.8 million for Q1 2026.
- In Q1 2026, EBITDA fell 14.67% year-over-year to -$48.8 million; the TTM figure through Mar 2026 stood at -$117.5 million (up 19.43% YoY), while the FY2025 annual figure was -$111.3 million, up 23.56% from the prior year.
- EBITDA for Q1 2026 stood at -$48.8 million, down from -$41.9 million in the prior quarter.
- The five-year high for EBITDA was $14.1 million in Q3 2025, with the low at -$48.8 million in Q1 2026.
- The 5-year median for EBITDA is -$30.6 million (2022), against an average of -$31.2 million.
- The sharpest annual moves came in 2022 and 2025: EBITDA sank 453.16% in 2022, then surged 142.8% in 2025.
- Tango Therapeutics' EBITDA stood at -$30.6 million in 2022, then decreased by 14.55% to -$35.0 million in 2023, then declined by 16.84% to -$40.9 million in 2024, then slipped by 2.33% to -$41.9 million in 2025, then dropped by 16.49% to -$48.8 million in 2026.
- Business Quant data shows TNGX's EBITDA at -$48.8 million in Q1 2026, -$41.9 million in Q4 2025, and $14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | -59.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.79 Mn |
| Mar 31, 2026 | -48.77 Mn |
| Dec 31, 2025 | -41.86 Mn |
| Sep 30, 2025 | 14.07 Mn |
| Jun 30, 2025 | -40.97 Mn |
| Mar 31, 2025 | -42.53 Mn |
| Dec 31, 2024 | -40.91 Mn |
| Sep 30, 2024 | -32.88 Mn |
| Jun 30, 2024 | -29.55 Mn |
| Mar 31, 2024 | -42.26 Mn |
| Dec 31, 2023 | -35.01 Mn |
| Sep 30, 2023 | -25.63 Mn |
| Jun 30, 2023 | -23.25 Mn |
| Mar 31, 2023 | -30.29 Mn |
| Dec 31, 2022 | -30.57 Mn |
| Sep 30, 2022 | -29.92 Mn |
| Jun 30, 2022 | -25.20 Mn |
| Mar 31, 2022 | -25.38 Mn |
| Dec 31, 2021 | -21.98 Mn |
| Sep 30, 2021 | -19.57 Mn |